Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases-Reference-Cited by-同舟云学术

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

Published:2019-02-19 Issue:3 Volume:145 Page:649-661
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Volckmar Anna-Lena¹,Leichsenring Jonas¹,Kirchner Martina¹,Christopoulos Petros²³⁴,Neumann Olaf¹,Budczies Jan¹⁵^ORCID,Morais de Oliveira Cristiano Manuel¹,Rempel Eugen¹,Buchhalter Ivo¹⁶,Brandt Regine¹,Allgäuer Michael¹,Talla Suranand Babu¹,von Winterfeld Moritz¹,Herpel Esther¹,Goeppert Benjamin¹,Lier Amelie¹,Winter Hauke³⁴⁷,Brummer Tilman⁸⁹,Fröhling Stefan¹⁰^ORCID,Faehling Martin¹¹,Fischer Jürgen R.¹²,Heußel Claus Peter³⁴¹³,Herth Felix³⁴¹⁴,Lasitschka Felix¹,Schirmacher Peter¹⁵,Thomas Michael²³⁴^ORCID,Endris Volker¹^ORCID,Penzel Roland¹,Stenzinger Albrecht¹⁵^ORCID

Affiliation:

1. Institute of Pathology; University Hospital Heidelberg; Heidelberg Germany

2. Department of Thoracic Oncology; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

3. Translational Lung Research Center Heidelberg (TLRC-H); member of the German Center for Lung Research (DZL); Heidelberg Germany

4. National Center for Tumor Diseases (NCT); Heidelberg Germany

5. German Cancer Consortium (DKTK), Heidelberg partner site; Germany

6. Division of Applied Bioinformatics; German Cancer Research Center (DKFZ); Heidelberg Germany

7. Department of Thoracic Surgery; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

8. Institute of Molecular Medicine and Cell Research, Faculty of Medicine; University of Freiburg; Freiburg Germany

9. German Cancer Consortium (DKTK) Partner Site Freiburg; German Cancer Research Center (DKFZ); Heidelberg Germany

10. Department of Translational Oncology; National Center for Tumor Diseases (NCT) Heidelberg; Heidelberg Germany

11. Department of Cardiology and Pneumology; Hospital Esslingen; Esslingen Germany

12. Department of Thoracic Oncology; Lungenklinik Löwenstein; Löwenstein Germany

13. Department of Diagnostic and Interventional Radiology with Nuclear Medicine; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

14. Department of Pneumology and Critical Care Medicine; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.32133/fullpdf

Reference60 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer;Pilkington;Thorax,2015

3. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future;Chan;Transl Lung Cancer Res,2015

4. Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung Cancer: results from the CA209-003 study;Gettinger;J Clin Oncol,2018

5. Updated molecular testing guideline for the selection of lung Cancer patients for treatment with targeted tyrosine kinase inhibitors;Lindeman;J Mol Diagn,2018

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study;European Journal of Cancer;2024-11

2. Plasma ofCS‐modified CD44 predicts the survival of patients with lung cancer;Cancer Science;2024-08-27

3. Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3;Journal of Cancer Research and Clinical Oncology;2024-06-20

4. Unravelling the puzzle of immunotherapeutic efficacy in lung cancer;Translational Lung Cancer Research;2024-05

5. Evaluation of Artificial Intelligence (AI)-basedin silicotools for variant classification in clinically actionable NSCLC variants;2024-04-14